Blurbs

Analysts Offer Insights on Healthcare Companies: Star Equity Holdings (STRR), Sutro Biopharma (STRO) and Pear Therapeutics (PEAR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Star Equity Holdings (STRRResearch Report), Sutro Biopharma (STROResearch Report) and Pear Therapeutics (PEARResearch Report) with bullish sentiments.

Star Equity Holdings (STRR)

Maxim Group analyst Tate Sullivan reiterated a Buy rating on Star Equity Holdings yesterday and set a price target of $2.25. The company’s shares closed last Monday at $0.90, close to its 52-week low of $0.72.

According to TipRanks.com, Sullivan is a 5-star analyst with an average return of 14.4% and a 41.1% success rate. Sullivan covers the Industrial Goods sector, focusing on stocks such as Natural Gas Services Group, Exro Technologies, and Globus Maritime.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Star Equity Holdings with a $2.25 average price target.

See the top stocks recommended by analysts >>

Sutro Biopharma (STRO)

Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Sutro Biopharma today and set a price target of $26.00. The company’s shares closed last Monday at $7.64.

According to TipRanks.com, Shu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -19.2% and a 31.9% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, POINT Biopharma Global, and Sensei Biotherapeutics.

Sutro Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $20.50, a 182.0% upside from current levels. In a report issued on November 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.

Pear Therapeutics (PEAR)

Chardan Capital analyst Keay Nakae maintained a Buy rating on Pear Therapeutics today and set a price target of $8.00. The company’s shares closed last Monday at $2.52, close to its 52-week low of $1.34.

According to TipRanks.com, Nakae is a 3-star analyst with an average return of 2.8% and a 38.6% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Arrowhead Pharmaceuticals, and Better Therapeutics, Inc.

Currently, the analyst consensus on Pear Therapeutics is a Strong Buy with an average price target of $6.00, implying a 101.3% upside from current levels. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $5.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on STRR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More